HCL-TECHNOLOGIES
27.2.2020 17:17:12 CET | Business Wire | Press release
HCL Foundation (HCLF), the Corporate Social Responsibility (CSR) arm of HCL Technologies, today announced the recipients of the fifth edition of HCL Grant in the presence of Padma Bhushan, Mr. Kapil Dev, a legend in the global world of cricket and former captain of the Indian Cricket team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200227005709/en/
HCL Grant is one of the biggest and most coveted institutionalized CSR grants in India that aims to recognize the rise of the Fifth Estate - the Non-Governmental Organizations (NGOs).
The evening was also graced by Mr. Shiv Nadar, Founder & Chairman, HCL, Ms. Roshni Nadar Malhotra, Vice Chairperson of HCL Technologies and the Chairperson of its CSR committee, and Mr. Prateek Aggarwal, Chief Financial Officer, HCL Technologies along with senior dignitaries, officials, NGO-partners and HCL leadership.
HCL Grant 2020 witnessed three NGOs across the categories of Education, Healthcare and Environment receiving a grant of ₹5 crores each. The remaining six finalists across the three categories also received ₹25 lakhs each, taking the overall Grant to ₹16.5 crore.
The finalists and the winners were selected by an eminent jury, which was chaired by Ms. Robin Abrams, Member of the Board, HCL Technologies.
Recipients of HCL Grant 2020:
-
Environment- The 2020 HCL Grant winner in this category is Under The Mango Tree Society.
Project Location: 4 districts (Gujarat, Maharashtra and Madhya Pradesh) -
Healthcare- The 2020 HCL Grant winner in this category is Operation ASHA.
Project Location: Kullu (Himachal Pradesh) -
Education- The 2020 HCL Grant winner in this category is Bal Raksha Bharat.
Project Location: Leh (Ladakh) and Budgam (J&K)
“It is extremely important to bring equal opportunities to people coming from every strata of the society. Health, Education and Environment are one of the most important pillars towards India’s development goals and I am highly impressed with the kind of impact these NGOs are bringing in the rural communities. Also, the robustness of the identification process is something I have not witnessed before. I congratulate both HCL as well the winners and finalists for the phenomenal work they are doing in their respective fields,” Mr. Kapil Dev said while addressing the audience at the event.
Excluding the current grant, HCL Grant has already disbursed ₹51.5 crores (US$ 7.4Mn) to benefit nearly 500,000 people and its supported projects aim to cover over a million people spread across 7,500 villages across 13 States and one Union Territory in the country.
“HCL Foundation is our long-term commitment for social development and today it has improved over 1.5 million lives across our country. Our collaborative model allows us to support communities with critical concerns needing immediate attention and HCL Grant is a prime example of the same. I am proud to say that today the improvements we have been able to drive together with the HCL Grant partner NGOs is not just in terms of immediate impact on beneficiary lives, but also about ensuring long-term sustainable change by influencing state and government policies,” said Ms. Roshni Nadar Malhotra, Vice-Chairperson, HCL Technologies and Chairperson, CSR Committee, HCL Technologies.
Ms. Nidhi Pundhir, Director HCL Foundation, said, “This is a very special year for us as we complete half a decade of empowering the NGOs that are committed to ushering change. This annual HCL Grant event is a culmination of our year-long efforts to identify partners who have the potential to achieve the maximum impact through their social development projects.. We are truly honored to have received applications from all parts of the country and my heartiest congratulations to the winning NGOs for giving us the opportunity to partner with them and support ideas for impactful positive change.”
HCL Foundation also released the compendium of the previous year’s finalists and winning NGOs, named “Fifth Estate – NGOs Transforming Rural India in Environment, Health and Education”.
For more information please visit www.hclfoundation.org/hcl-grant .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200227005709/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
